1. Home
  2. NMFC vs DRUG Comparison

NMFC vs DRUG Comparison

Compare NMFC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

HOLD

Current Price

$7.65

Market Cap

650.8M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$79.22

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMFC
DRUG
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
650.8M
778.4M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
NMFC
DRUG
Price
$7.65
$79.22
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$8.63
$129.25
AVG Volume (30 Days)
524.7K
162.2K
Earning Date
05-04-2026
05-15-2026
Dividend Yield
15.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.73
$38.00
52 Week High
$10.71
$123.75

Technical Indicators

Market Signals
Indicator
NMFC
DRUG
Relative Strength Index (RSI) 57.94 52.06
Support Level $7.49 $76.54
Resistance Level $8.17 $83.65
Average True Range (ATR) 0.16 3.64
MACD 0.00 -0.39
Stochastic Oscillator 57.14 31.21

Price Performance

Historical Comparison
NMFC
DRUG

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: